	US 12,102,673 B2
	Zika virus vaccine
Jana Barbero Calzado, Vienna (AT); Mario Nebenführ, Vienna (AT); Robert Schlegl, Siegenfeld (AT); Michael Weber, Vienna (AT); and Jürgen Heindl-Wruss, Vienna (AT)
Assigned to Valneva Austria GMBH, Vienna (AT)
Filed by Valneva Austria GmbH, Vienna (AT)
Filed on Jun. 14, 2023, as Appl. No. 18/334,497.
Application 18/334,497 is a continuation of application No. 17/548,721, filed on Dec. 13, 2021, granted, now 12,005,111.
Application 17/548,721 is a continuation of application No. 16/813,862, filed on Mar. 10, 2020, granted, now 11,219,681.
Application 16/813,862 is a continuation of application No. 16/063,007, granted, now 10,639,365, previously published as PCT/EP2016/082664, filed on Dec. 23, 2016.
Claims priority of application No. 15202585 (EP), filed on Dec. 23, 2015; application No. 16161068 (EP), filed on Mar. 18, 2016; application No. 16176025 (EP), filed on Jun. 23, 2016; application No. 16176049 (EP), filed on Jun. 23, 2016; and application No. 16182845 (EP), filed on Aug. 4, 2016.
Prior Publication US 2024/0108712 A1, Apr. 4, 2024
Int. Cl. A61K 39/12 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61P 31/14 (2006.01); C07K 14/18 (2006.01); C12N 7/00 (2006.01); C12N 7/02 (2006.01); C12N 7/06 (2006.01)

CPC A61K 39/12 (2013.01) [A61K 39/39 (2013.01); A61P 31/14 (2018.01); C07K 14/18 (2013.01); C07K 14/1825 (2013.01); C12N 7/00 (2013.01); C12N 7/02 (2013.01); C12N 7/06 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/55505 (2013.01); C12N 2770/24134 (2013.01); C12N 2770/24151 (2013.01); C12N 2770/24163 (2013.01); Y02A 50/30 (2018.01)]

32 Claims

1. A Zika virus vaccine comprising a Zika virus having an RNA genome, wherein said Zika virus vaccine is capable of stimulating a neutralizing antibody titer greater than 15 in at least 70% of vaccinated subjects, wherein the neutralizing antibody titer is determined using a microneutralization assay (MN50) following a single administration of the Zika virus vaccine to a subject; and wherein the Zika virus comprises an E protein having an amino acid sequence having at least 95% sequence identity to any one of SEQ ID NOs: 14-69 and is able to pack a virulent Zika virus.